Literature DB >> 15925987

Comparative genetic analysis of metachronous anaplastic oligoastrocytomas with extended recurrence-free interval.

Ramon Martinez1, Hans-Konrad Schackert, Matthias Kirsch, Werner Paulus, Stefan Joos, Gabriele Schackert.   

Abstract

Two metachronous anaplastic oligoastrocytomas with different cerebral locations were analyzed in a 51-year-old patient with an extended recurrence-free interval of 6 years and an a long survival of 9 years. Remarkably, the patient had not undergone adjuvant chemotherapy. Different cytogenetic and molecular techniques were performed including comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), allelic loss analysis, sequencing of p53, p16(INK4a)/CDKN2A and p14(ARF), EGFRamplification studies, investigation of the DNA mismatch repair system as well as tumor clonality. Using CGH and FISH a profile of low accumulation of cytogenetic aberrations was found in the second tumor, with no significant increase in the percentage of hyperdiploid nuclei. Microsatellite analysis showed a common pattern of allelic losses at 1p36, 19q13 and 9p21. Both specimens were also similar in that they retained heterozygosity at 10q23-q24 and 13q14 and that they harbor neither EGFR amplification nor mutations of p53, p16(INK4a)/CDKN2A or p14(ARF). The only further alteration in the second tumor was an allelic loss at p53. The X-chromosome inactivation (HUMARA) analysis revealed a polyclonal pattern in both samples. Our data strongly suggest that the second anaplastic oligoastrocytoma developed as a distant relapse of the first tumor. Whether the paucity of accumulation of the observed genetic alterations might be associated with the unusually extended relapse-free time of the patient remains to be elucidated.

Entities:  

Mesh:

Year:  2005        PMID: 15925987     DOI: 10.1007/s11060-004-3347-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  31 in total

1.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Molecular genetic evidence for subtypes of oligoastrocytomas.

Authors:  D Maintz; K Fiedler; J Koopmann; B Rollbrocker; S Nechev; D Lenartz; A P Stangl; D N Louis; J Schramm; O D Wiestler; A von Deimling
Journal:  J Neuropathol Exp Neurol       Date:  1997-10       Impact factor: 3.685

3.  Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.

Authors:  S H Bigner; M R Matthews; B K Rasheed; R N Wiltshire; H S Friedman; A H Friedman; T T Stenzel; D M Dawes; R E McLendon; D D Bigner
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

4.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype.

Authors:  J S Smith; B Alderete; Y Minn; T J Borell; A Perry; G Mohapatra; S M Hosek; D Kimmel; J O'Fallon; A Yates; B G Feuerstein; P C Burger; B W Scheithauer; R B Jenkins
Journal:  Oncogene       Date:  1999-07-15       Impact factor: 9.867

5.  Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization.

Authors:  J W Jeuken; S H Sprenger; P Wesseling; M V Macville; A von Deimling; H L Teepen; J J van Overbeeke; R H Boerman
Journal:  J Neuropathol Exp Neurol       Date:  1999-06       Impact factor: 3.685

6.  Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma.

Authors:  Kolja Freier; Stefan Joos; Christa Flechtenmacher; Frauke Devens; Axel Benner; Franz X Bosch; Peter Lichter; Christof Hofele
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

7.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

8.  Clonality of oligoastrocytomas.

Authors:  Zhi-Qian Dong; Jesse Chung-Sean Pang; Carol Yuen-Kwan Tong; Liang-Fu Zhou; Ho-Keung Ng
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

9.  Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization.

Authors:  S Joos; U S Bergerheim; Y Pan; H Matsuyama; M Bentz; S du Manoir; P Lichter
Journal:  Genes Chromosomes Cancer       Date:  1995-12       Impact factor: 5.006

10.  Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease.

Authors:  C L Willman; L Busque; B B Griffith; B E Favara; K L McClain; M H Duncan; D G Gilliland
Journal:  N Engl J Med       Date:  1994-07-21       Impact factor: 91.245

View more
  3 in total

1.  Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma.

Authors:  David W Nauen; Andrew Guajardo; Lisa Haley; Kerry Powell; Peter C Burger; Christopher D Gocke
Journal:  Converg Sci Phys Oncol       Date:  2015-06-16

Review 2.  Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

Authors:  Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Sebastian Brandner; Luke Vale; Julian Pt Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2022-03-02

3.  Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event.

Authors:  Ulrike Lass; Astrid Nümann; Kajetan von Eckardstein; Jürgen Kiwit; Florian Stockhammer; Jörn A Horaczek; Julian Veelken; Christel Herold-Mende; Judith Jeuken; Andreas von Deimling; Wolf Mueller
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.